Prime editing method corrects cystic fibrosis in stem cells
A team of scientists used a CRISPR-Cas9 technique known as prime editing to correct cystic fibrosis in cultured human stem cells.
List view / Grid view
Stem cells are undifferentiated biological cells that can differentiate into specialised cells and can divide to produce more stem cells.
A team of scientists used a CRISPR-Cas9 technique known as prime editing to correct cystic fibrosis in cultured human stem cells.
The latest edition of the live-cell analysis handbook is a companion guide for live-cell analysis users. Includes discussion of live-cell analysis.
This whitepaper overviews the importance of understanding T Cell Biology to build better therapeutics, demonstrates use of advanced flow cytometry.
30 July 2021 | By Bio-Techne
Watch this on-demand webinar and learn about robust technologies for nanobody drug discovery.
JDRF funds development of an insulin-producing implant to regulate blood glucose levels in type 1 diabetes patients.
Depletion of ATP due to viral-induced CPE leads to a reduction in luminescence signal, enabling quantitation of viral-induced CPE in host cells.
28 July 2021 | By Sartorius AG
In this on-demand webinar, our expert illustrates the utility of GPCR libraries and explains how to discover potent functional antibodies against multiple GPCR targets.
A Swiss team have created a laboratory test that incorporates the placenta into embryotoxicity assessments without damaging foetuses.
New research has shown that the protein Piezo 1 prevented Treg cells from controlling the effects of inflammation in a multiple sclerosis mouse model.
Researchers have developed a 3D “assembloid” that presents a potential entry route of COVID-19 into the brain.
A team have developed a minimally invasive exosome spray that helped repair rat hearts after myocardial infarction.
Every manufacturing process for potential biologics begins with cell line development, whether it’s for clinical trials or a market launch.
10 reasons to choose Bethyl antibodies and reagents from Fortis Life Sciences for your applications.
Researchers have published a step-by-step protocol on how to produce millions of mature human cells in a chimeric mouse embryo.
As interest in biotherapeutic proteins grows, the need to reduce cell line development costs and the time to market is more critical than ever.